NCT04728321已完成2 期
An Open-Label Multi-Center Phase II Study of Anti-PD-1/CTLA-4 Bispecific Antibody AK104 Alone or in Combination With Lenvatinib in Patients With Advanced Hepatocellular Carcinoma
Akeso1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2021年1月27日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Objective response rate (ORR)
研究概览
简要总结
An open-label multi-center phase II study to evaluate the efficacy and safety of anti-PD-1/CTLA-4 bispecific antibody AK104 alone or in combination with lenvatinib in patients with advanced hepatocellular carcinoma.
详细描述
This is a multi-center, multi-cohort, open-label phase 2 clinical study to evaluate the anti-tumor activity, safety, PK profile, immunogenicity and potential biomarkers of AK104 alone or in combination with for the treatment of advanced hepatocellular carcinoma
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent form voluntarily.
- •Histologically or cytologically documented hepatocellular carcinoma.
- •BCLC stage C, and non-resectable BCLC stage B .
- •At least one measurable lesion according to RECIST criteria.
- •ECOG of 0 or
- •Adequate organ function.
- •Estimated life expectancy of ≥3 months.
- •For women of childbearing potential: agreement to remain abstinent; For men: agreement to remain abstinent
排除标准
- •Histologically or cytologically documented fibrolamellar hepatocellular carcinoma, sarcoma-like hepatocellular carcinoma, cholangiocarcinoma, etc.
- •History of hepatic encephalopathy or liver transplantation.
- •Clinical significance of hydrothorax, ascites or pericardial effusion.
- •Central nervous system metastases and/or carcinomatous meningitis.
- •Any risk of bleeding; severe bleeding tendency or coagulation dysfunction, or under thrombolytic therapy.
- •Occurred arteriovenous thromboembolic events within 6 months before the first administration.
- •Tumor volume > 50% liver volume; portal vein tumor thrombus or inferior vena cava tumor thrombus.
- •Inadequately controlled arterial hypertension.
- •Attack of symptomatic congestive heart failure (LVEF<50%); History of congenital long QT syndrome.
- •Known presence or history of interstitial lung disease or required hormone treatment interstitial lung disease.
- •Severe infections.
- •Receipt of any anti-tumor treatment, chemotherapy, targeted therapy, immunotherapy,
- •Enrollment of another clinical study within 4 weeks prior to the first administration of study drugs.
- •Unable to receive an enhanced CT or MRI scan of the liver.
结局指标
主要结局
Objective response rate (ORR)
时间窗: Up to 2 years
ORR is defined as the proportion of subjects with confirmed CR or PR, based on RECIST v1.1.
次要结局
- Progression-free survival (PFS)(Up to 2 years)
- Disease control rate (DCR)(Up to 2 years)
- Number of participants with adverse events (AEs)(the time of informed consent signed through 90 days after the last dose of AK104 and Lenvatinib)
- Duration of response (DoR)(Up to 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular CarcinomaHepatocellular CarcinomaNCT04444167Akeso59
已完成
1 期
A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung CancerSCLC,Extensive StageNCT05505825Akeso36
招募中
2 期
Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung CancerOncologyNSCLC Stage IVNSCLC, Stage IIINCT05344209Vestre Viken Hospital Trust138
已完成
2 期
Study of BGB-A317 in Participants With Previously Treated Unresectable HCCHepatocellular Carcinoma (HCC)NCT03419897BeiGene249
尚未招募
2 期
Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint InhibitorsUterine Cervical NeoplasmsCancer of CervixCervical NeoplasmsUterine Cervical CancerCancer of the Uterine CervixCervical CancerNCT05824494Women's Hospital School Of Medicine Zhejiang University58